Blog

Boomers Drive $8.3 Trillion Longevity Economy: Unlocking Opportunities for Smart Businesses

Hannah Perry | January 20, 2025

Boomers are Good for Business: The ‘Longevity Economy’ is the New Gold Rush The aging population, particularly the baby boomer generation, represents a largely overlooked yet lucrative market often referred to as the “longevity economy.” This demographic group defies outdated stereotypes and is financially empowered, tech-savvy, and diverse in their lifestyles and preferences. With an…

Cannabis Industry Leaders Form U.S. Cannabis Roundtable to Push for Federal Reform Under Trump Administration

Hannah Perry | January 17, 2025

Cannabis Groups Unite to Advocate for Federal Reform under Trump Administration In a significant development for the legal cannabis industry, several of America’s largest cannabis companies are joining forces to establish the U.S. Cannabis Roundtable. This new advocacy group aims to address the legislative stagnation surrounding marijuana reform at the federal level, as President-elect Donald…

UnitedHealth’s Earnings Report: Key Insights and Expectations for Investors Amidst Turmoil

Hannah Perry | January 16, 2025

UnitedHealth’s Earnings Report: A Crucial Moment for Investors As UnitedHealth Group Inc. prepares to release its fourth-quarter earnings report, expectations are higher than ever—not just for the financial figures but for the narrative surrounding the company. This pivotal moment comes in the wake of Brian Thompson’s shocking death, the head of the UnitedHealthcare unit, and…

Eli Lilly’s Stock Plummets 8.2% Amid Disappointing Mounjaro and Zepbound Sales Forecast

Hannah Perry | January 15, 2025

Mounjaro and Zepbound Sales Disappoint, Eli Lilly’s Stock Takes Major Hit Shares of Eli Lilly & Co. are experiencing a steep decline, signaling what could be the company’s most significant selloff in four years. This downturn comes on the heels of disappointing revenue forecasts for the fourth quarter, linked to slower-than-anticipated growth in sales of…

Moderna Stock Crashes to Lowest Point Post-COVID as Revenue Forecast Falls Flat

Hannah Perry | January 14, 2025

Moderna’s Stock Plummets to Post-COVID Lows Amid Disappointing Revenue Outlook Shares of Moderna Inc. (MRNA) took a significant hit in early trading on Monday, falling nearly 20% after the biotechnology company issued a downbeat revenue forecast for the upcoming years. With projections indicating a steep decline in revenue and an announcement of accelerated cost-cutting measures,…

J.P. Morgan Healthcare Conference 2023: Navigating Uncertainty and Hopes for M&A Revival

Hannah Perry | January 13, 2025

J.P. Morgan Healthcare Conference Kicks Off Amidst Sector Struggles The Mood Aligns with Performance The 43rd annual J.P. Morgan Healthcare Conference, a key gathering for healthcare investors and executives, is set to begin in San Francisco on Monday, yet the atmosphere is far from festive. In stark contrast to the upbeat historical tone of past…

Medicare Coverage Boosts Eli Lilly’s Zepbound as a Game Changer for Sleep Apnea Treatment

Hannah Perry | January 10, 2025

Medicare Approval Creates Opportunity for Eli Lilly’s Zepbound in Sleep Apnea Treatment In a significant development for Eli Lilly & Co., the Centers for Medicare and Medicaid Services (CMS) has confirmed that Medicare Part D plans can now cover the company’s obesity drug Zepbound as a treatment for obstructive sleep apnea (OSA). This news comes…

Moderna’s Bold Bet on China’s Pharmaceutical Market Amid U.S. Retreat

Hannah Perry | January 9, 2025

Moderna Is Gambling on China as Other U.S. Companies Pull Back In a bold move that contrasts sharply with the retreat of many U.S. companies from the Chinese market, Moderna has made a significant decision to deepen its investments in China. The biotechnology firm announced in 2023 that it would initiate research, development, and manufacturing…

Moderna Stock Soars 12%: Essential Price Levels and Trends to Watch

Hannah Perry | January 8, 2025

Moderna Price Levels to Watch After Stock’s 12% Surge on Tuesday Moderna (MRNA) experienced a significant uptick on Tuesday, with shares surging 12% to close at $47.53. This surge comes amid investor optimism regarding the pharmaceutical company’s development of a vaccine for the H5N1 bird flu, especially following the first reported death linked to the…

Next Page »